Investment Thesis

.

Competitive Moat

primarily through its intangible assets, encompassing a rich portfolio of intellectual property, regulatory approvals, and established brand reputation in diagnostics and life sciences. The company's long-standing relationships with healthcare providers, research institutions, and government bodies further fortify its position, creating high switching costs for its customers. Over the next 5-10 years, this moat appears durable, although the increasing competition from emerging biotech firms and other established players in the diagnostics space poses a notable threat.

Growth Engine

Future revenue growth for Revvity is expected to derive from a combination of new product innovations, geographic expansion, and increasing demand for diagnostic testing. The global diagnostics market is projected to grow at a CAGR of approximately 5.6%, providing a substantial total addressable market (TAM) for Revvity's offerings. Additionally, the company's focus on new technologies, such as next-generation sequencing and genomic workflows, positions it well to capture market share, particularly as public awareness of genetic testing and early disease detection rises.